MetLife Investment Management LLC Raises Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

MetLife Investment Management LLC increased its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 129.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,596 shares of the company’s stock after purchasing an additional 13,859 shares during the quarter. MetLife Investment Management LLC owned approximately 0.05% of Shattuck Labs worth $86,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. FMR LLC lifted its stake in shares of Shattuck Labs by 0.4% during the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock worth $24,985,000 after purchasing an additional 26,460 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after purchasing an additional 502,860 shares during the last quarter. Pinnacle Associates Ltd. lifted its stake in shares of Shattuck Labs by 15.0% during the 2nd quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock worth $2,314,000 after purchasing an additional 78,177 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Shattuck Labs by 83.1% during the 2nd quarter. Renaissance Technologies LLC now owns 392,010 shares of the company’s stock worth $1,513,000 after purchasing an additional 177,910 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after purchasing an additional 150,340 shares during the last quarter. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Shattuck Labs Price Performance

Shares of NASDAQ:STTK opened at $1.30 on Wednesday. The business’s 50-day moving average is $1.26 and its 200 day moving average is $3.27. Shattuck Labs, Inc. has a 1 year low of $0.94 and a 1 year high of $11.76. The firm has a market capitalization of $62.06 million, a P/E ratio of -0.82 and a beta of 1.76.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research note on Friday, November 15th. Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research report on Wednesday, October 2nd. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research report on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs currently has an average rating of “Hold” and a consensus target price of $8.67.

Insider Activity

In other news, CEO Taylor Schreiber acquired 36,500 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were acquired at an average cost of $1.21 per share, with a total value of $44,165.00. Following the completion of the acquisition, the chief executive officer now owns 71,002 shares of the company’s stock, valued at approximately $85,912.42. This trade represents a 105.79 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Redmile Group, Llc acquired 133,371 shares of the business’s stock in a transaction dated Wednesday, December 4th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $166,713.75. Following the completion of the acquisition, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. This trade represents a 2.47 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 10.50% of the company’s stock.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.